Message from the Managing Director
It's been a busy quarter for Proteomics International, with the announcement of two key manufacturing milestones for our PromarkerD test for diabetic kidney disease—ISO 13485 certification and the groundwork for a scale-up of production of immunoassay reagents and kits. At the same time, we're progressing our bid for US FDA approval for PromarkerD with the regulatory body.
Our pipeline of diagnostics under development is evolving well, and we now have four biomarker research programs at the ‘clinical validation’ stage—endometriosis, Giardia
, oxidative stress and oesophageal cancer.
Also in this newsletter, we have included a list of planned conferences for 2021 – the team has been busy generating new results on the performance of PromarkerD, which we look forward to presenting to global audiences.
Finally—we're expanding again! Our executive team is set to be bolstered by the appointment of a Chief Commercialisation Officer and Chief Financial Officer to help accelerate our growth in global markets.
Dr Richard Lipscombe